Zim Laboratories Ltd
Zim Laboratories Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #35 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires. FY28 growth expected at 30-40% top-line if EU-GMP certification is obtained, leading to mid-teens EBITDA margin (Page 12).
From Zim Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires.
- FY28 growth expected at 30-40% if EU-GMP certification is obtained, with major value unlock from EU market entry.
- Revenue projection for FY28 around INR 500 crores subject to EU-GMP certification.
- Sales from innovative product portfolio and regulated market (NIP and Oral Thin Film) expected to contribute significantly post EU-GMP.
- Growth driven by expansion into regulated markets, new product launches, and improved organizational capabilities.
- Lag of about two quarters expected between EU-GMP certification and start of substantial supply and revenue impact.
2 more points from Zim Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Zim Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CapEx for FY27 is mostly completed.
- Remaining CapEx mainly involves normal upgradation expenses.
- Planned CapEx of around INR 15-20 crores to upgrade the enzyme plant and Nutra plant.
2 more points from Zim Laboratories Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Zim Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has mentioned having 8 to 10 Market Authorizations (MAs) awaiting activation once EU-GMP certification is obtained.
- Some products are already being produced at alternate facilities as a risk mitigation measure.
- Inventory buildup is selective, focused on APIs for key products with longer lead times; other inventory is managed on a just-in-time basis.
- Orders from Australia have started, with supplies expected to begin within 2-3 months pending TGA certification.
2 more points from Zim Laboratories Ltd's call on order book
Create a free account to keep reading this call
Zim Laboratories Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹105 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Zim Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Zim Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Zim Laboratories Ltd Q1 FY27 results?
FY27 growth expected at 10-15% without EU-GMP certification, driven by base business and new hires. FY28 growth expected at 30-40% top-line if EU-GMP certification is obtained, leading to mid-teens EBITDA margin (Page 12).
What is Zim Laboratories Ltd share price analysis?
Zim Laboratories Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 141.2 with a market cap of ₹614 Cr. Investors should review the full earnings analysis for detailed insights.
Is Zim Laboratories Ltd planning capital expenditure?
CapEx for FY27 is mostly completed.
Keep Zim Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.